SecBot SecBot
8-K/A ·Filed Mar 5, 2026

AIPG

AI Technology Group Inc.
NEUTRAL
Impact 5/10
Horizonmonths Processed7mo ago SEC0001477932-26-001191
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight • Neutral

Monitor whether Tranche 3 funding ($10–25M) is delivered by July 26, 2026, as failure could jeopardize the merger. The extension suggests audit delays; watch for subsequent filings on financials or further delays.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d ⚠ clustered
AIPG ▲ 0.00% at T+60d
NEUTRAL call 0.00% · α vs SPY -12.78% · entry $2.50 → $2.50
Entry = T+0 close
Mar 5, 2026
via day close
T+1d
0.00%
call 0.00% · α -0.85%
$2.50
settled 8mo ago
T+5d
0.00%
call 0.00% · α +1.53%
$2.50
settled 8mo ago
T+20d
0.00%
call 0.00% · α +2.04%
$2.50
settled 7mo ago
T+60d
0.00%
call 0.00% · α -12.78%
$2.50
settled 5mo ago

Price Chart

Loading chart...

Executive Summary

AI Technology Group Inc. (AIPG) amended its merger agreement with AVM Biotechnology Inc. and Biomed 360 Solutions Corp. to extend the closing date from March 31, 2026, to July 26, 2026, due to financial audit obligations. The amendment also confirms and adjusts investment tranches totaling up to $25 million, with loans convertible into shares at $2.50 per share and accruing 10% annual interest.

Key Financial Metrics

Deal Type
merger

Key Facts

  • Closing date for the merger extended from March 31, 2026, to July 26, 2026
  • Tranche 1: $1M loan provided by August 1, 2025, convertible at $1.00/share
  • Tranche 2: $1M provided by November 20, 2025, with three additional $1M installments due by February 28, April 30, and June 30, 2026, all convertible at $2.50/share
  • Tranche 3: $10M–$25M to be provided before closing, convertible at $2.50/share
  • Tranche 2 and 3 loans accrue 10% annual simple interest, settled in shares at $2.50/share
  • AMENDMENT CORRECTS AVM'S JURISDICTION FROM NEVADA TO WASHINGTON

Financial Impact

Up to $25 million in convertible debt financing, with $3 million already committed in Tranches 1 and 2 and $10–25 million pending in Tranche 3

debtdilutioncashFlow

Risk Factors

  • Failure to secure Tranche 3 funding could collapse the merger
  • Extended timeline increases execution risk and potential for further delays or termination
  • Significant share dilution upon conversion of up to $28M in loans at prices between $1.00 and $2.50 per share

Market Snapshot

Exchange
OTC

Investment Themes

Industrials & Manufacturing

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K/A Filing (Primary)0001477932-26-001191
Document: aipg_ex10.htm0001477932-26-001191
Document: 0001477932-26-001191-index-headers.html0001477932-26-001191
Document: 0001477932-26-001191-index.html0001477932-26-001191
Document: 0001477932-26-001191.txt0001477932-26-001191
3 reports for AIPG
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for AIPG — sortable, filterable
TypeNow
Oct 2, 2026
24d ago
8-K
BEARISH ★ 7/10
$2.50 $2.50· 0.00%▲ +1.16%$2.50 (0.00%)
Mar 5, 2026
33w ago
8-K/A
BEARISH ★ 7/10
$2.50 $2.50· 0.00%▼ −1.53%$2.50 (0.00%)
Mar 5, 2026
33w ago
8-K/A
NEUTRAL ★ 5/10
$2.50 $2.50· 0.00%▲ +1.53%$2.50 (0.00%)
Showing 3 of 3

US Market Status

Market Closed — Opens Wed (11h 55m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 5, 2026